Theriva™ Biologics to Present at the NeauxCancer Conference
Theriva™ Biologics (NYSE American: TOVX), a pioneering clinical-stage enterprise based in Rockville, is on the forefront of developing innovative therapeutics aimed at addressing cancer and related diseases, particularly in areas where there is a significant unmet medical need. The company’s management has announced an important upcoming engagement at the NeauxCancer 2025 Conference, scheduled to occur from March 27th to 29th.
Event Highlights and Company Presentation
During this conference, taking place at The Roosevelt New Orleans Hotel, Theriva™ will be featured in the Innovation track, specifically on March 28th at 9:00 AM. This track is dedicated to showcasing emerging biotech and healthcare companies that are making headway in cancer detection and treatment technologies. The opportunity for Theriva™ to present its cutting-edge research is a testament to the importance of its contributions to oncology.
Networking and One-on-One Meetings
Theriva’s management team will make themselves available for one-on-one meetings throughout the duration of the conference. This invites interested investors and stakeholders to engage directly with the leadership of Theriva™, facilitating discussions that could propel the future of cancer therapies. Those interested in scheduling a meeting are encouraged to reach out to the provided investor relations representative.
Advancing Cancer Treatment Technologies
Theriva™ Biologics specializes in crafting specialized therapeutics that aim to enhance the way cancer is treated. A key component of their strategy is the development of a novel oncolytic adenovirus platform designed for diverse delivery methods, including intravenous (IV) and intravitreal applications. The objective is clear: to stimulate tumor cell death while enhancing the delivery of existing cancer therapies to tumors, ultimately promoting a strong immune response against cancers.
The Company’s Pioneering Candidates
Among the standout candidates in Theriva's pipeline are:
- VCN-01: This is an oncolytic adenovirus tailored to replicate specifically within tumor cells, reducing resistance that often complicates cancer treatment.
- SYN-004 (ribaxamase): Crafted to mitigate the detrimental effects of commonly used IV beta-lactam antibiotics on the gut microbiome, it strives to prevent issues like the overgrowth of harmful pathogens and the severity of acute graft-versus-host disease (aGVHD) in patients undergoing hematopoietic cell transplants.
- SYN-020: Offered as a recombinant oral formulation of intestinal alkaline phosphatase (IAP), it aims to treat various local gastrointestinal and systemic diseases.
These innovative approaches place Theriva™ Biologics as a leading entity in the quest for viable cancer therapies.
Contact and Further Information
For more details regarding Theriva™ Biologics and its cutting-edge projects, stakeholders can tap into their official website. Individuals interested in reaching out for additional information or inquiries can contact Kevin Gardner from LifeSci Advisors. More specific details are shared as follows:
Contact Details
Investor Relations:
Kevin Gardner
LifeSci Advisors, LLC
Email: kgardner@lifesciadvisors.com
Phone: 617-283-2856
Frequently Asked Questions
What is Theriva™ Biologics focusing on?
Theriva™ Biologics is dedicated to developing therapeutics designed to combat cancer and other related diseases.
When is the NeauxCancer 2025 Conference?
The conference will take place from March 27th to March 29th, 2025.
Where can I learn more about Theriva™ Biologics?
For more information, visit the official website of Theriva™ Biologics.
How can I schedule a meeting with Theriva™ during the conference?
Interested individuals should contact Theriva’s investor relations representative for meeting arrangements.
What innovative products does Theriva™ have in development?
Theriva™'s pipeline includes VCN-01, SYN-004, and SYN-020, each targeting specific challenges in cancer treatment.
